Organoid-based personalized medicine: from tumor outcome prediction to autologous transplantation

Abel Soto-Gamez,Jennifer P Gunawan,Lara Barazzuol,Sarah Pringle,Robert P Coppes

DOI: https://doi.org/10.1093/stmcls/sxae023

IF: 5.845

2024-03-26

Stem Cells

Abstract:Inter-individual variation largely influences disease susceptibility, as well as response to therapy. In a clinical context, the optimal treatment of a disease should consider inter-individual variation and formulate tailored decisions at an individual level. In recent years, emerging organoid technologies promise to capture part of an individual's phenotypic variability and prove helpful in providing clinically relevant molecular insights. Organoids are stem cell-derived three-dimensional models that contain multiple cell types that can self-organize and give rise to complex structures mimicking the organization and functionality of the tissue of origin. Organoids represent thus a more faithful recapitulation of the dynamics of the tissues of interest, compared to conventional monolayer cultures, thus supporting their use in evaluating disease prognosis, or as a tool to predict treatment outcomes. Additionally, the individualized nature of patient-derived organoids enables the use of autologous organoids as a source of transplantable material not limited by histocompatibility. An increasing amount of preclinical evidence has paved the way for clinical trials exploring the applications of organoid-based technologies, some of which are in phase I/II. This review focuses on the recent progress concerning the use of patient-derived organoids in personalized medicine, including (1) diagnostics and disease prognosis, (2) treatment outcome prediction to guide therapeutic advice and (3) organoid transplantation or cell-based therapies. We discuss examples of these potential applications and the challenges associated with their future implementation.

oncology,cell biology,hematology,biotechnology & applied microbiology,cell & tissue engineering

What problem does this paper attempt to address?

This paper discusses the application of organoids in personalized medicine, particularly in tumor prognosis, treatment prediction, and autologous transplantation. Organoids are three-dimensional cell structures derived from patient cells, which can simulate the complexity and function of native tissues and better reflect inter-individual differences compared to traditional two-dimensional cell cultures.

The paper points out that organoid technology can be used for disease diagnosis and prognosis analysis. For example, intestinal organoids can be used to study autoimmune diseases such as Crohn's disease, or lung organoids can be used to study the sensitivity to respiratory viral infections. In oncology, tumor organoids can predict the efficacy of chemotherapy or radiotherapy, providing a basis for personalized treatment plans.

In addition, the autologous transplantation characteristics of organoids make them a potential source of cell therapy, especially for normal tissue organoids that are not limited by tissue compatibility. Despite challenges such as cell type diversity, cell-cell interactions, extracellular matrix composition, and stem cell sources, organoids have shown potential in clinical trials, particularly in cancer treatment.

The paper summarizes ongoing clinical trials covering various types of organoids and disease areas, including but not limited to brain cancer, breast cancer, lung cancer, gastrointestinal cancer, and genetic diseases. These trials aim to validate the effectiveness of organoids in predicting treatment response, guiding treatment decisions, and conducting cell transplantation therapy.

Overall, this paper aims to highlight the latest advancements and future challenges of organoid technology in personalized medicine, demonstrating its promising prospects in improving disease prognosis, optimizing treatment choices, and realizing autologous transplantation therapy.